Innovative Drug Commercial Insurance Catalog

Innovative drug commercial insurance catalog is the payment-policy branch added by 156.生物医药的2026：当市场不再为BD躁动，中国药企的星辰大海才刚刚展开. The episode says China’s first commercial-insurance innovative-drug catalog was formally created in 2025, with a July setup and a December first catalog in the source’s timeline.

The catalog is not the same as basic national medical insurance. The source emphasizes that it is a recommendation to commercial insurers, with final inclusion still depending on insurer decisions. Its significance is that Chinese innovation drugs may receive a payment channel outside the basic医保 price-control logic.

Key Claims

• Payment policy affects innovation-drug commercialization as much as approval or BD.
• The first catalog included negotiated high-price drugs such as CAR-T products in the source’s account.
• Commercial insurers still decide what they actually cover, so policy signal and real access can diverge.
• The policy shift supports Biotech BD Data Validation Phase by making 2026 a test of payment adoption, not only clinical data.

Connections

• National Healthcare Security Administration / 国家医保局 - payer-side institution associated with the catalog.
• CAR-T Cell Therapy - high-cost therapy category named in the source.
• Unmet Medical Need Demand Pull, Clinical Development Capability, and Global Pharma Commercialization - demand, evidence, and market-access context.